We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+12.78%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$450M
AUM Growth
+$20.6M
Cap. Flow
+$23.6M
Cap. Flow %
5.23%
Top 10 Hldgs %
53.49%
Holding
51
New
15
Increased
13
Reduced
3
Closed
15

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$16M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$15.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
4
PASG icon
Passage Bio
PASG
+$12.4M
5
RNAM
Avidity Biosciences
RNAM
+$11.9M

Top Sells

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$29.4M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$16.1M
3
UTHR icon
United Therapeutics
UTHR
+$16M
4
BIIB icon
Biogen
BIIB
+$13.4M
5
SAGE
Sage Therapeutics
SAGE
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Real Estate 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KDMN
51
DELISTED
Kadmon Holdings, Inc.
KDMN
– –
-3,375,000
Closed -$29.4M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Great Point Partners held 51 positions worth $450M, up 4.8% from $429M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Great Point Partners deployed $23.6M of net new capital in Q4 2021, opening 15 new positions and adding to 13 existing holdings. Its largest new stake was Relmada Therapeutics: 717,320 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $7.21M trimmed.

  • Great Point Partners's largest Q4 2021 buy was Relmada Therapeutics: 717,320 shares worth $16.2M.
  • Great Point Partners added most to Vaxcyte in Q4 2021, an estimated $9.35M increase.
  • Great Point Partners's biggest Q4 2021 reduction was Rocket Pharmaceuticals, cutting an estimated $7.21M.
  • Great Point Partners fully exited Kadmon Holdings, Inc. in Q4 2021, selling an estimated $29.4M.
  • Great Point Partners's ten largest holdings make up 53% of its $450M portfolio in Q4 2021.
  • Great Point Partners opened 15 new positions and closed 15 in Q4 2021.
  • Great Point Partners's portfolio value rose 4.8% quarter-over-quarter to $450M.

Based on Great Point Partners's 13F filing for Q4 2021, filed 14 Feb 2022.